AB Science delays AML, ALS trial restarts after “for-cause” GCP inspection by EU health authorities

Bitget2026/09/29 06:10

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

AB Science revised its development plan following a “for cause” sponsor Good Clinical Practice inspection by French, Danish, Greek authorities.
Clinical study restarts now depend on health-authority benefit-risk assessments, pending a final inspection report expected before year-end.
Phase 1 AB8939 trial in acute myeloid leukemia targeted to resume in Q1 2027, subject to regulator clearance.
Masitinib Phase 3 ALS trial restart pushed to Q4 2027, subject to a new inspection and regulator clearance.
Half-year financial report publication delayed to Oct. 9, 2026 due to resources diverted to the inspection response.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB Science SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290207PRIMZONEFULLFEED1001275091) on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

AB Science delays AML, ALS trial restarts after “for-cause” GCP inspection by EU health authorities

You may also like

Crypto prices